Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Prednisolone sodium phosphate
Drug ID BADD_D01833
Description Prednisolone phosphate is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone phosphate was granted FDA Approval on 19 December 1973.[L14144]
Indications and Usage For the treatment of primary or secondary adrenocortical insufficiency, such as congenital adrenal hyperplasia, thyroiditis. Also used to treat psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, bursitis, acute gouty arthritis and epicondylitis. Also indicated for treatment of systemic lupus erythematosus, pemphigus and acute rhematic carditis. Can be used in the treatment of leukemias, lymphomas, thrombocytopenia purpura and autoimmune hemolytic anemia. Can be used to treat celiac disease, insulin resistance, ulcerative colitis and liver disorders.
Marketing Status Prescription; Discontinued
ATC Code A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID DB14631
KEGG ID D00981
MeSH ID C009022
PubChem ID 441409
TTD Drug ID Not Available
NDC Product Code 50383-040; 52128-164; 42799-812; 65089-0007; 66993-844; 62135-330; 59212-700; 71052-610; 42799-813; 50090-1582; 10695-109; 64958-0042; 0121-0759; 59212-702; 24002-0007; 81646-118; 63187-215; 22552-0051; 66993-846; 24208-715; 0121-0777; 67296-1505; 66993-845; 44523-182; 38779-0153; 65162-667; 50090-0955; 59212-701; 62991-1205; 0121-0773; 68788-7708; 49452-5995; 68791-104; 70166-549; 13925-166; 22552-0004; 17856-0759; 0121-0902; 49452-5996; 60432-212; 51927-0050
Synonyms prednisolone phosphate | Predsol | prednisolone sodium phosphate | prednisolone phosphate, sodium salt, (11beta)-isomer | prednisolone 21-phosphate sodium | prednisolone phosphate sodium | prednisolone phosphate, monosodium salt, (11beta)-isomer | prednisolone-21-phosphate | Pediapred
Chemical Information
Molecular Formula C21H27Na2O8P
CAS Registry Number 125-02-0
SMILES CC12CC(C3C(C1CCC2(C(=O)COP(=O)([O-])[O-])O)CCC4=CC(=O)C=CC34C)O.[Na+].[Na+]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypoglycaemia14.06.03.001; 05.06.03.001--
Hypokalaemia14.05.03.002--
Hypokalaemic syndrome14.05.03.003--Not Available
Hypoparathyroidism14.04.01.007; 12.02.15.001; 05.04.02.001--
Hypopituitarism05.03.02.001--
Hypotension24.06.03.002--
Impaired healing08.03.02.001--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Increased insulin requirement14.06.01.006; 05.06.01.006--Not Available
Increased tendency to bruise23.06.01.009; 01.01.03.005; 24.07.06.012--Not Available
Infection11.01.08.002--Not Available
Injury12.01.08.004--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Intracranial pressure increased17.07.02.002--Not Available
Intraocular pressure increased13.07.04.002--Not Available
Irritability08.01.03.011; 19.04.02.013--
Joint stiffness15.01.02.003--Not Available
Laryngeal pain22.02.05.036--
Lethargy19.04.04.004; 08.01.01.008; 17.02.04.003--
Leukocytosis01.02.01.002--
Malaise08.01.01.003--
Mania19.16.02.002--
Menstruation irregular21.01.01.005; 05.05.01.008--
Mood swings19.04.03.001--Not Available
Muscle disorder15.05.03.014--Not Available
Muscular weakness17.05.03.005; 15.05.06.001--
Myalgia15.05.02.001--
Myopathy15.05.05.001--Not Available
Nausea07.01.07.001--
Nervousness19.06.02.003--Not Available
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages